GlassScriptPhysician profile
Jenny S Lee
NPI 1508821836
$3,386.56
in general payments reported to CMS, 2019-2025
32 companies · $698 in 2025
The $698 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $33.87 · 2021: $488 · 2022: $406 · 2023: $778 · 2024: $635 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,111.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.15 | 2021-2025 | |
| Novo Nordisk INC | $422.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $402.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $309.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $183.07 | 2019-2025 | Farxiga, Fasenra, Breztri |
| Novartis Pharmaceuticals Corporation | $182.72 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $154.36 | 2019-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $120.67 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $120.00 | 2019-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $112.18 | 2021-2024 | Eliquis |
| Abbott Laboratories | $104.94 | 2021-2023 | Freestyle Libre |
| Lilly USA, LLC | $102.83 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $83.10 | 2019-2025 | Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $71.87 | 2021-2022 | |
| Amarin Pharma, INC. | $69.56 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $56.13 | 2019-2021 | |
| Exact Sciences Corporation | $50.60 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $40.04 | 2025 | Symbravo, Auvelity |
| Dexcom, INC. | $37.86 | 2024 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $28.88 | 2023 | Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $25.55 | 2021-2024 | Trintellix |
| Ibsa Pharma INC. | $23.06 | 2022 | |
| Boston Scientific Corporation | $22.85 | 2024 | Wavewriter Alpha Prime 16 |
| Allergan, INC. | $19.73 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.60 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.97 | 2022 | |
| Merck Sharp & Dohme LLC | $18.32 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.40 | 2022 | |
| Zealand Pharma US, INC. | $14.57 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.55 | 2025 | Zoryve |
| Medtronic, INC. | $14.53 | 2023 | Inpen Smart Insulin Delivery System |
| Cequr Corporation | $7.91 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.